Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
1. Presented by – Dr shailendra Kumar Tiwari
Moderator – Dr Majibullah Ansari
2. Water comprise 60% of typical healthy man and 50% women’s body weight.
Intracellular compartment (ICF) -- 55-65%
Extracelluar compartment (ECF) -----35-45%.
75% of extracellular fluid is in interstitial space and 25 % is in intravascular space.
Sodium is the major extracellular cation. Normal sodium concentration is 135-145
mEq/l.
3. The most common electrolyte disturbances observed in hospitalized patients
Defined as serum [Na+ ] < 135 mmol/L
Majority of dysnatremias arise from a primary imbalance in electrolyte-free water
intake and loss.
The perturbation in water balance rather than any change in salt content is the
problem.
4. Body fluid concentration -- regulated by --hypothalamic-pituitary axis to influence
water intake through thirst and water excretion via the effect of vasopressin on
renal collecting duct water permeability.
Depending on its severity and chronicity, hyponatremia can lead to significant
symptoms, primarily related to central nervous system function.
Failure to correct ---permanent neurologic damage, also occers in over rapid
correction.
Essential to stay within specific limits for correction, particularly for chronic
hyponatremia.
5. Plasma osmolality, defined as the concentration of osmoles dissolved per kilogram
of plasma water.
Osmolarity is the concentration of osmoles per liter of plasma water.
Plasma osmolality is a colligative property that is directly measurable with an
osmometer.
Tonicity, which is potentially confused with osmolality, denotes the concentration of
effective osmoles— that do not freely cross cell membranes.
6. Plasma tonicity cannot be measured directly but is calculated by subtracting the
contribution of urea to the measured plasma osmolality
Plasma osmolality, mOsm/kg H2O:
(2 × [Na+] + BUN (mg/dL)/2.8 + glucose (mg/dL)/18
Plasma tonicity, mOsm/kg H2O:
Measured plasma osmolality − BUN (mg/dL)/2.8 or (2 × [Na+] + glucose (mg/dL)/18
7. Isotonic hyponatremia or Pseudohyponatremia
Hypertonic hyponatremia OR Translocational hyponatremia
Hypotonic Hyponatremia- true hyponatremia
8. Apparent hyponatremia with osmolality of 275 to 295 mOsm/kg H2O .
Not a true hyponatremia but laboratory artifact.
High plasma lipid or protein--- lower the aqueous contribution to plasma volume,
leading to a falsely decreased calculated [Na+ ] value.
Direct potentiometry--- commonly used in blood gas analyzers, is not subject to
this error.
9. Hyponatremia with plasma tonicity > 295 mOsm/kg H2O
Most commonly observed in hyperglycemia.
Efflux of water into the extracellular space, in turn decreasing the [Na+ ].
[Na+ ] decreases by1.6 mEq/L for every 100 mg/dL increase in serum glucose
level.
As serum glucose level increases to >400 mg/dL, the incremental decrease in [Na+
] can approximate 2.4 mEq/ L.
10. Low UOsm indicative of maximally dilute urine—typically < 100 mOsm/kg H2O
Vasopressin is appropriately suppressed but water ingestion exceeds the kidney’s
capacity for electrolyte-free water excretion ----Primary polydipsia
If solute ingestion diminishes to 200 mOsm/d, -- “tea-and-toast” diet or beer
potomania
Electrolyte free water excretory capacity decreases to 4 L/ d (200 mOsm solute/50
mOsm/kg H2O = 4 L)--- risk for hypotonic hyponatremia despite modest fluid
intake and preserved urinary dilution
11. Hypovolemia: Hyponatremia Associated With Decreased Total Body Sodium
Hypervolemia: Hyponatremia Associated With Increased total Body Sodium
Euvolemia: Hyponatremia Associated With Normal Total Body Sodium
12. Hypovolemic hypotonic hyponatremia may occur as a consequence of true
intravascular volume depletion of any cause, including
Hemorrhage
Gastrointestinal fluid loss,
Diuretics
Salt wasting due to mineralocorticoid deficiency in Addisonian crisis.
cerebral salt wasting can complicate subarachnoid hemorrhage and lead to hypovolemic
hyponatremia
13. Hypervolemic hypotonic hyponatremia can is a consequence of decompensated
heart failure or advanced cirrhosis.
CHF --hypoperfusion -- reduced effective circulating volume --- vasopressin
release and water retention.
Cirrhosis --- splanchnic vasodilation ---arterial underfilling provokes--
vasopressin release --hyponatremia.
As a surrogate, hyponatremia is a strong predictor of mortality.
Serum [Na+ ] of less than 125 mmol/l reflects severe CHF
14.
15. Nephrotic syndrome, especially in MCD---low plasma oncotic pressure from
hypoalbuminemia---- intravascular volume contraction---- stimulation of AVP with
hyponatremia.
Advanced CKD ---severely reduced GFR---Edema develops when the Na+ ingested
exceeds the capacity of the kidneys to excrete this load.
Likewise, if water intake exceeds threshold, there is positive water balance and
hyponatremia.
16. The leading cause, SIADH---persistent vasopressin secretion in the absence of an
osmotic or hemodynamic stimulus.
SIADH requires other causes of euvolemic hypotonic hyponatremia with
impaired urinary dilution be excluded.
Cortisol inhibits vasopressin release, isolated glucocorticoid deficiency manifests
as euvolemic hyponatremia with hypoglycemia
Hyponatremia occurs in patients with severe hypothyroidism. A decrease in
cardiac output leads to nonosmotic release of AVP.
17.
18.
19. Acute psychosis develop hyponatremia.
Psychogenic drugs---selective serotonin reuptake inhibitors (SSRIs)
Psychosis can cause hyponatremia independently.
The pathophysiologic process is increased thirst perception, a mild defect in
osmoregulation that causes AVP to be secreted at lower osmolality
Marathon runners are at highest risk for exercise-associated hyponatremia, which
arises from nonosmotic vasopressin release in the setting of pain, stress, or
discomfort coupled with excessive ingestion of hypotonic fluids.
20.
21.
22.
23.
24.
25.
26. STEP WISE INVESTIGATIONS FOR
HYPONATREMIA
Step 1: Measurement of serum sodium
Step 2-Measurement of Serum osmolality
Step 3: Urine osmolality
STEP 4: URINE SODIUM
In hypovolemic hyponatremic patients who have metabolic alkalosis caused by
vomiting, the urine sodium concentration may be greater than 20 meq/L, but the
urine chloride concentration will be low (less than 20 meq/L).
27. STEP WISE INVESTIGATIONS FOR
HYPONATREMIA
Step 5: Serum uric acid and urea concentrations
Serum uric acid is often low ( < 4 mg/dl) in patients with SIADH. in contrast,
patients with hypovolemic hyponatremia will be hyperuricemic due to a shared
activation of proximal tubular Na+-Cl– and urate transport
Step 6 Acid-base and potassium balance
Metabolic alkalosis and hypokalemia - diuretic use or vomiting
Metabolic acidosis and hypokalemia - diarrhea or laxative abuse
Metabolic acidosis and hyperkalemia - primary adrenal insufficiency and renal failure
Normal acid base and potassium - in the SIADH
28. STEP WISE INVESTIGATIONS FOR
HYPONATREMIA
Step 7- Saline infusion
in case of doubt, one can initiate 0.9% NaCl infusion with monitoring of serum
sodium and follow-up at 6 to 8 h.
Hypovolemic hyponatremia improves with 0.9% NaCl while hyponatremia in
SIADH may not be corrected and usually worsens with 0.9% NaCl
administration.
29. Treatment of Hypertonic Hyponatremia
Translocational hyponatremia secondary to hyperglycemia improve with lowering
of blood glucose level.
Aggressive volume repletion with isotonic fluid is required to correct volume
depletion from the glucosuria-driven osmotic diuresis and make up for
intracellular translocation of water with glucose in response to insulin
30. While a brain cell depleted of its organic osmolytes resists swelling in a hypotonic
environment
Brain cell dehydrate and shrink if its surrounding tonicity increases faster than it
can reaccumulate effective osmoles.
Osmotic demyelination syndrome (ODS) occur if correction of hyponatremia is
achieved too rapidly.
31. Sequelae of ODS are often irreversible and include dysphagia, dysarthria,
spasticity, behavioral disturbance, cognitive impairment, delirium, seizures,
quadriparesis, coma, and “locked in” syndrome.
Most commonly affected area is pons
Other regions of the brain affected in ODS: (in order of frequency) cerebellum,
lateral geniculate body, thalamus, putamen, and cerebral cortex or subcortex. .
32. ODS classically presents several days after an initial treatment-induced
improvement in the neurologic symptoms from the hyponatremia itself.
Because of this delay, over rapid correction should be promptly addressed despite
the lack of any symptoms.
33.
34. acute hypotonic hyponatremia --less than 24 to 48 hours lacks complete brain
adaptation -- carries no risk for ODS.
ODS is also unlikely to complicate treatment --with an initial [Na+ ] > 125 mEq/L.
Patients with chronic hypotonic hyponatremia, a presenting [Na+ ] < 105 mEq/L,
alcoholism, advanced liver disease, and malnutrition are notable risk factors for ODS.
Because potassium is exchangeable with sodium, repletion of potassium deficits leads
to translocation of sodium out of cells and a further increase in [Na+ ]; hypokalemia is
also a risk factor for ODS.
35. Normalization of [Na+ ] in acute hyponatremia carries no risk for ODS, the rate of
increase need not be constrained when the duration of hyponatremia is known to
be less than 48 hours.
In a key retrospective study of 56 patients treated for chronic hyponatremia with
a [Na+ ] < 105 mEq/L, posttherapeutic neurologic complications did not occur
among patients for whom [Na+ ] corrected < 12 mEq/L in 24 hours or <18 mEq/L
in 48 hours.
They were absent as well in patients for whom [Na+ ] increased <0.55 meq/l/hr per
hour to a concentration of 120 mEq/L
36.
37. Beyond chronicity, the severity of attributable symptoms should also guide
therapy.
Chronic hyponatremia have mild or no symptoms-- provides ample time to fix the
electrolyte disturbance gradually.
Severely symptomatic with marked alterations in sensorium or seizures, rapid
elevation of the [Na+ ] (irrespective of presumed duration of hyponatremia) by just
4 to 6 mEq/L in 1 to 2 hours ---reduce brain swelling and abort any seizure or
seizure risk.
This can be accomplished by administration of up to three 100-mL boluses of
hypertonic saline solution given 10 minutes apart
38. Electrolyte-free water restriction can prevent worsening hyponatremia
irrespective of the cause. Thiazide diuretic treatment should be discontinued.
39. a [Na+] ≤ 105 mEq/L, hypokalemia, alcoholism, malnutrition, and advanced liver disease.
40. Impaired urinary dilution due to hypovolemia ---volume repletion with isotonic
fluids such as 0.9% saline solution or Ringer’s lactate solution.
Because restoration of euvolemia is accompanied by suppression of nonosmotic
vasopressin release--- abrupt onset of a brisk water diuresis -- risk for over rapid
correction of [Na+ ].
41. For both heart failure and cirrhosis, fluid and salt restriction are cornerstones of
treatment,
Loop diuretics -- first-line therapy for hyponatremia due to heart failure.
loop diuretics tend to impair free-water reabsorption.
They can be cautiously used in cirrhosis as well.
When fluid restriction and loop diuretics fail, a vasopressin antagonist (vaptan)
used as second line therapy for mild to moderate symptomatic hyponatremia
related to heart failure.
Caution is indicated before the use of a vaptan in patients with cirrhosis due to
their to cause splanchnic vasodilatation (conivaptan) or hepatotoxicity (tolvaptan)
42. Hypothyroidism or isolated glucocorticoid deficiency--- fluid restriction plus
hormone replacement therapy.
SIADH -- eliminating its cause.
SIADH due to pulmonary or central nervous system infection resolve with
appropriate antimicrobial therapy.
Treatment with culprit medications should be discontinued, if possible.
Beyond treating the cause, SIADH is also initially managed with water
restriction.
43. The urine-to plasma electrolyte ratio (urinary [Na+] + [K+]/plasma [Na+]) --used
as a quick indicator of electrolyte-free water excretion.
Patients with a ratio of >1 should be more aggressively restricted (500 ml/day)
those with a ratio of ~1 should be restricted to 500–700 mL/d, and those with a
ratio <1 should be restricted to <1 liter /day.
Fluid restriction alone is unlikely to be successful in many cases of SIADH when
the underlying cause is persistent.
44. Two pharmacologic therapies -- vaptans and the osmotic agent urea
Conivaptan-- nonselective vasopressin V1 and V2 receptor inhibitor.
Tolvaptan is V2 selective.
conivaptan increased [Na+ ]-- 8 mEq/L over several days
Tolvaptan increased [Na+ ] -- 5 mEq/L over 4 days when administered at a
starting dose of 15 mg titrated up to 60 mg daily.
Approximately 2% of patients given tolvaptan experienced over rapid correction of
[Na+]
Some patients will be exquisitely sensitive and others will be relatively refractory.
Careful monitoring of [Na+ ] changes is thus required when vaptans are initiated.
45. Conivaptan - potent CYP3A4 inhibitor with many drug-drug interactions.
although orally active, it received US FDA approval in only an IV formulation for
short-term use.
Long-term tolvaptan use is limited by 2 factor--- liver damage is a relative
contraindication for long-term tolvaptan use.
The more important factor precluding long-term tolvaptan use is its cost, rs 120
for a single 15 mg tablet.
These agents are suitable when the duration of the underlying cause of
hyponatremia is expected to be brief, as with pneumonia-induced SIADH or when
[Na+ ] must be increased for a specific reason, such as an upcoming surgical
procedure.
46. Side effects for both tolvaptan and conivaptan are thirst, dry mouth, and polyuria.
Vaptans should not be used in concert with hypertonic saline solution owing to
case reports of associated ODS.
Urea is a long-standing and less-expensive alternative to the vaptans for
treatment of SIADH.
Excreted in urine, it increases urinary solute content and electrolyte-free water
clearance.
7.5 to 90 g/d of urea is associated with an 6-mEq/L increase in [Na+ ] over 4 to 5
days.
Urea is not associated with serious adverse events such as [Na+ ] overcorrection.
47. Neither vaptans nor urea have been well studied in severe symptomatic
hyponatremia.
Patients with [Na+ ] < 120 mEq/L and attributable neurologic symptoms were
excluded from vaptan trial.
Accordingly, at the present time, without further data, vaptans or urea should be
considered for use only in patients with euvolemic or hypervolemic hyponatremia
with mild to moderate symptoms, and not in circumstances in which [Na+ ] must
be increased emergently.
48.
49. When hypertonic saline solution is used or severe hyponatremia complicates
profound hypovolemia, [Na+ ] measured ---every 2 to 4 hours.
In thiazide-induced and hypovolemic hyponatremia, aquaresis may follow the
suppression of nonosmotic vasopressin release that occurs after volume repletion.
This can result in a rapid increase in [Na+ ].
Because the increase will be preceded by an increase in urine output and decrease
in UOsm, urine output should be monitored hourly and UOsm should be
measured frequently in this setting.
50. If overcorrection occurs, calculation of urine electrolyte-free water excretion can
guide therapy .
Administering enteral water or IV 5% dextrose in water in an amount equal to
urinary electrolyte-free water loss plus estimated extrarenal and insensible water
losses should prevent a further increase in [Na+ ].
If overcorrection occurs---therapeutic relowering of the [Na+ ].--- increasing the
calculated rate of enteral water or IV 5% dextrose in water administration by 3
mL/kg/h.
Electrolyte-free water excretion: Urine Volume × (1 − (UNa + UK)/[Na+])
51. In patients at high risk for over rapid correction due to aquaresis---preemptive
desmopressin, 1 - 2 μg, IV or subcutaneously every 6 hours to prevent any urine
electrolyte-free water loss with 3% saline solution infused at a rate calculated to
effect the desired rate of increase in [Na+ ].
Irrespective of the strategy adopted, adherence to the recommended daily
maximal [Na+ ] increase limit and frequent laboratory monitoring are key
requirements for avoidance of ODS.